S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:IPA

ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

$1.52
-0.05 (-3.18%)
(As of 03/28/2024 ET)
Today's Range
$1.50
$1.64
50-Day Range
$1.40
$2.41
52-Week Range
$0.94
$4.22
Volume
320,153 shs
Average Volume
1.66 million shs
Market Capitalization
$40.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

ImmunoPrecise Antibodies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
360.5% Upside
$7.00 Price Target
Short Interest
Healthy
2.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of ImmunoPrecise Antibodies in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.36) to ($0.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

651st out of 938 stocks

Pharmaceutical Preparations Industry

305th out of 435 stocks

IPA stock logo

About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPA Stock Price History

IPA Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
IPA Announces Proposed Public Offering of Common Shares
See More Headlines
Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Fiscal Year End
4/30/2024
Next Earnings (Estimated)
7/08/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IPA
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+360.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,980,000.00
Pretax Margin
-66.12%

Debt

Sales & Book Value

Annual Sales
$15.61 million
Book Value
$1.40 per share

Miscellaneous

Free Float
24,518,000
Market Cap
$40.01 million
Optionable
Not Optionable
Beta
0.12
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Jennifer Lynne Bath Ph.D.
    CEO, President & Non-Independent Director
  • Dr. Ilse Roodink
    Chief Scientific Officer & Interim General Manager of IPA Europe, Oss
  • Ms. Kristin Taylor CPA
    M.B.A., Chief Financial Officer
  • Mr. David E. Orton
    Chief Operating Officer
  • Dr. Roland Romijn
    Head of General Operations of the Utrecht site of IPA (Europe)

IPA Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoPrecise Antibodies stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPA shares.
View IPA analyst ratings
or view top-rated stocks.

What is ImmunoPrecise Antibodies' stock price target for 2024?

2 equities research analysts have issued 12 month price targets for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $5.00 to $9.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 360.5% from the stock's current price.
View analysts price targets for IPA
or view top-rated stocks among Wall Street analysts.

How have IPA shares performed in 2024?

ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of 2024. Since then, IPA stock has decreased by 11.1% and is now trading at $1.52.
View the best growth stocks for 2024 here
.

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 440,700 shares, an increase of 1,290.2% from the February 29th total of 31,700 shares. Based on an average trading volume of 571,700 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.0% of the company's shares are short sold.
View ImmunoPrecise Antibodies' Short Interest
.

When is ImmunoPrecise Antibodies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 8th 2024.
View our IPA earnings forecast
.

Who are ImmunoPrecise Antibodies' major shareholders?

ImmunoPrecise Antibodies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.87%), Northern Trust Corp (0.23%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners